Previous 10 | Next 10 |
SAN DIEGO , Sept. 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Cantor Global Healthcare Conference in New York, NY . Dr. Helen Torley , presiden...
A Phase 3 clinical trial, FeDeriCa , evaluating the subcutaneous (SC) administration of a fixed-dose combination of Roche's ( OTCQX:RHHBY ) Herceptin (trastuzumab) and Perjeta (pertuzumab) plus chemo in patients with HER2-positive early-stage breast cancer showed it to be non-inferior to ...
Halozyme Therapeutics (NASDAQ: HALO ) announces that the global phase III FeDeriCa study conducted by Genentech, met its primary endpoint. The study investigated a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) for subcutaneous administration using Halozyme's EN...
SAN DIEGO , Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its ...
The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with this Read more ...
SAN DIEGO , Aug. 26, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Wells Fargo Healthcare Conference in Boston, MA. Dr. Helen Torley , president and...
Halozyme Therapeutics, Inc. (HALO) Q2 2019 Earnings Conference Call August 6, 2019 16:30 ET Company Participants Albert Kildani - VP, IR & Corporate Communications Helen Torley - President, CEO & Director Laurie Stelzer - SVP & CFO Alison Armour - SVP, R&D Co...
Halozyme Therapeutics (NASDAQ: HALO ): Q2 GAAP EPS of -$0.10 beats by $0.05 . More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , Aug. 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the second quarter ended June 30, 2019 and provided an update on recent corporate a...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...